[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xingjun Guo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100636137","phase-2-adebrelimab-plus-s-1-for-resected-cholangiocarcinoma-100636137",false,"NCT07561775","Adebrelimab Plus S-1 for Resected Cholangiocarcinoma","A Single-Arm, Exploratory Clinical Study of Adebrelimab Combined With S-1 in Patients With Resected Cholangiocarcinoma","Inclusion Criteria:\n\n* Histologically or pathologically confirmed malignant cholangiocarcinoma.\n* Patients who have undergone curative surgical resection.\n* Age between 18 and 75 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Expected survival time \\>3 months.\n* Adequate organ and bone marrow function, including:Absolute neutrophil count ≥1.5 × 10\\^9\u002FL,Platelet count ≥75 × 10\\^9\u002FL,Hemoglobin ≥90 g\u002FL,Total bilirubin ≤1.5 × upper limit of normal (ULN),AST and ALT ≤2.5 × ULN,Albumin ≥3 g\u002FdL,Serum creatinine ≤1.5 × ULN.\n* Ability to understand and willingness to sign written informed consent.\n* For patients of childbearing potential, willingness to use effective contraception during the study and for at least 1 month after the last dose; negative pregnancy test within 72 hours prior to enrollment.\n\nExclusion Criteria:\n\n* Prior treatment with immune checkpoint inhibitors or other agents targeting T-cell co-stimulatory or co-inhibitory pathways (e.g., CTLA-4, CD137).\n* Use of any investigational drug within 4 weeks prior to enrollment.\n* Active autoimmune disease or history of autoimmune disease (e.g., interstitial lung disease, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, or hypothyroidism requiring hormone replacement).\n* Known immunodeficiency, including HIV infection, active hepatitis B (HBV DNA \\>500 IU\u002FmL), active hepatitis C (HCV RNA above detection limit), or co-infection of HBV and HCV.\n* Severe infection within 4 weeks prior to first dose or unexplained fever \\>38.5°C during screening.\n* History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Uncontrolled psychiatric disorders.\n* Severe or uncontrolled comorbidities that may interfere with study participation (e.g., unstable angina, myocardial infarction within 6 months, symptomatic arrhythmia, congestive heart failure, uncontrolled diabetes, or uncontrolled infection).\n* History of other malignancies within the past 5 years, except for non-melanoma skin cancer or carcinoma in situ.\n* Known hypersensitivity to study drugs or monoclonal antibodies.\n* Inability or unwillingness to provide informed consent.","ALL","18 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn whether adebrelimab combined with S-1 works as an adjuvant treatment for patients with cholangiocarcinoma after curative surgery. It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\n* Does adebrelimab combined with S-1 reduce the risk of cancer recurrence after surgery?\n* What side effects do participants experience when receiving this treatment? All participants in this study will receive adebrelimab combined with S-1. There is no comparison group in this study.\n\nParticipants will:\n\n* Receive adebrelimab by intravenous infusion once every 3 weeks for 4 cycles\n* Take S-1 by mouth twice daily for 4 weeks, followed by a 2-week rest, for 4 cycles\n* Visit the hospital regularly for checkups, laboratory tests, and imaging examinations (CT or MRI)\n* Be followed up for safety and survival after completing treatment",[27,28],"Cholangiocarcinoma","Biliary Tract Cancer",[30,31,32,33,34,35],"Adebrelimab","S-1","Adjuvant Therapy","Postoperative Treatment","PD-L1 Inhibitor","Immunotherapy","NOT_YET_RECRUITING","2026-04-25",{"date":39,"type":40},"2026-05-01","ACTUAL",{"date":42,"type":21},"2026-04-21",{"date":44,"type":21},"2032-01-01",{"name":46,"class":47},"Xingjun Guo","OTHER",""]